Alterity Therapeutics has shown its Multiple System Atrophy drug ATH-434 has a potential market value of US$2.4 billion if approved. ... Read More The post StockTake: Alterity’s ATH434 shows US$2.4b ...
After menopause, women with MS show accelerated loss of volume in brain structures associated with memory, attention, and problem-solving.
As they explained in their case report in the Journal of Neurology and Neuroscience, ophthalmologic examination identified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback